BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 29027074)

  • 1. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    Lin C; Bradshaw T; Perk T; Harmon S; Eickhoff J; Jallow N; Choyke PL; Dahut WL; Larson S; Humm JL; Perlman S; Apolo AB; Morris MJ; Liu G; Jeraj R
    J Nucl Med; 2016 Dec; 57(12):1872-1879. PubMed ID: 27445292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
    Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of
    Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of quantitative analysis in
    Lapa P; Marques M; Costa G; Lima JP
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):78-84. PubMed ID: 27793635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
    Simoncic U; Perlman S; Liu G; Jeraj R
    Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative
    Coskun N; Cagdas B; Yildirim N
    Hell J Nucl Med; 2022; 25(2):132-137. PubMed ID: 35913859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Response to Tumor Necrosis Value-α Blocker Is Suggested by
    Kim K; Son SM; Goh TS; Pak K; Kim IJ; Lee JS; Kim SJ
    AJR Am J Roentgenol; 2020 Jun; 214(6):1352-1358. PubMed ID: 32286869
    [No Abstract]   [Full Text] [Related]  

  • 17. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
    Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of
    Jeon TJ; Kim S; Park J; Park JH; Roh EY
    BMC Med Imaging; 2018 Sep; 18(1):34. PubMed ID: 30236078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Body [
    Muzi M; O'Sullivan F; Perk TG; Muzi JP; Mankoff DA; Jeraj R; Duan F; Yu EY
    Tomography; 2021 Apr; 7(2):139-153. PubMed ID: 33923126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.